Marck Biosciences expands capacity with Rs 72 crore

Ahmedabad, May 9 (UNI) Intravenous fluid manufacturing company Marck Biosciences (MBL) has expanded its large and small volume parental capacity at a cost of Rs 72 crore at its Kheda unit, about 40 from here.

The fresh investment of Rs 72 crore towards creating additional capacity of its large volume parental (LVP) and small volume parental would enable Marck to enhance its product basket in sterile dosages, MBL managing director Bhavesh Patel told mediapersons at the plant today.

''With this, the total investment at the existing campus would exceed Rs 125 crore and revenue would be in excess of Rs 105 crore,'' Mr Patel said.

This also includes setting up a modern formulation and development centre, along with a modern laboratory and a training centre for the human resource department.

Last year, Marck commissioned its latest sterile dosage facility for manufacturing ophthalmic products, respiratory range and small volume injectables, he said.

''Marck would be focusing on marketing its ophthalmic and respiratory products in advanced markets like the US, Canada, UK, Europe, South Africa, Australia and Brazil,'' Mr Patel said.

The expansion programme would increase the company's capacity for intravenous (IV) fluids and sterile diluents, he added.

UNI MP GK SKB1653